Friday, May 15, 2026, San Antonio, Texas, 12:15 PM – 1:45 PM Central Time (1:15 PM – 2:45 PM Eastern Time)
Recent Advances in Cancer Care — New Paradigms, Novel Agents and What It Means for the Oncology Nurse: Targeting the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer
A Complimentary NCPD Symposium Held During the 51st Annual ONS Congress
Program Schedule — Central Time
11:45 AM – 12:15 PM — Registration and Lunch
12:15 PM – 1:45 PM — Educational Meeting
Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, Texas
Hotel Phone: (210) 223-1000
Meeting Room
Grand Ballroom A-F (Third Floor)
Faculty Reva Basho, MD
Chief Medical Officer
Ellison Medical Institute
Los Angeles, California
Kelly Fischer, MSN, FNP-BC
Family Nurse Practitioner
Dana-Farber Cancer Institute
Boston, Massachusetts
Melissa Rikal, FNP-BC, AOCNP
Nurse Practitioner
Sarah Cannon Research Institute
Nashville, Tennessee
Moderator Seth Wander, MD, PhD
Director of Precision Medicine
Termeer Center for Targeted Therapies
Director of Translational Research
Breast Oncology Program
Massachusetts General Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Meeting space has been assigned to provide a symposium supported by AstraZeneca Pharmaceuticals LP and Genentech, a member of the Roche Group, during the Oncology Nursing Society’s (ONS) 51st Annual Congress, May 13-17, 2026 in San Antonio, TX. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
Program Schedule — Central Time
11:45 AM – 12:15 PM — Registration and Lunch
12:15 PM – 1:45 PM — Educational Meeting
Topics to Be Discussed
Identification of Appropriate Candidates with Hormone Receptor (HR)-Positive Metastatic Breast Cancer (mBC) for Agents Targeting the PI3K/AKT/mTOR Pathway
Role of Inavolisib in the Management of HR-Positive mBC
Adverse Events Associated with Inavolisib
Clinical Utility of Capivasertib in the Management of HR-Positive mBC
Side Effects and Other Practical Considerations with Capivasertib
Potential Role of Gedatolisib in the Management of HR-Positive mBC
Tolerability Profile of Gedatolisib
Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer.
Learning Objectives
Upon completion of this activity, participants should be able to
Review available research documenting the correlation between various biomarkers, such as PIK3CA/AKT1/PTEN alterations and ESR1 mutations, and response to specific therapies, and understand optimal testing algorithms for patients with hormone receptor (HR)-positive metastatic breast cancer (mBC).
Recognize the frequency of PIK3CA/AKT/PTEN alterations in HR-positive mBC, and educate patients with newly diagnosed and relapsed/refractory disease about evidence-based approaches to targeting these aberrations.
Understand the biological rationale for the development of agents targeting multiple components of the PI3K/AKT/mTOR pathway, and recognize available and emerging data with this strategy for patients with HR-positive, PIK3CA wild-type and PIK3CA-mutant mBC.
Assess the spectrum, frequency and severity of adverse events associated with available and emerging agents targeting the PI3K/AKT/mTOR pathway, and consider recommended approaches to prevent, ameliorate and manage these side effects.
Evaluate available research findings with and ongoing studies evaluating novel PI3K/AKT/mTOR inhibitor-based approaches, and consider the potential role of these strategies.
Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.
This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.
Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This program will be submitted for ONCC/ILNA certification.
Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.
Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.
FACULTY To be announced.
MODERATOR To be announced.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.
Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Genentech, a member of the Roche Group.
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000
Meeting Room
Grand Ballroom A-F (Third Floor)
Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer.
No registration fee is charged for this event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.
NOTICE Registration for this event is independent of registration for the 2026 ONS Congress.
IN-PERSON registration for nurses and healthcare providers
I am a practicing nurse or healthcare provider involved in the care of patients with cancer.
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.
Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.